Shockwaves added to early zoster care · Comparison study · 2026
Does adding shockwave to early shingles care ease the pain?
In this hospital study, people who added six shockwave sessions to usual shingles care saw pain fall from about 7 to about 1 out of 10 by three months after leaving hospital, against under 3 with usual care alone. Fewer developed lasting nerve pain: 2 of 41 against 13 of 41.
Possible early help for shingles pain- adults aged 50–80 with new shingles pain
- 82
- sessions over 3 weeks
- 6
- months of follow-up after leaving hospital
- 3
Good to know: Not randomised: doctors and patients chose who had shockwave. Everyone also got antiviral and pain medicines.
Cheng F, Yu Y, Zhang J Medicine (Baltimore), 2026 · Read the paper ↗
How this study worked
Conceptual animation: a focused front converges, then spreads. Not to scale. Tap the field to send a pulse.
What happened
Shingles pain
0–10 pain scale · start and three months after leaving hospital
Start3 months after leaving hospital
Show the numbers
| Group | People | Start | 3 months after leaving hospital |
|---|---|---|---|
| Shockwave + usual care | 41 | 7.1 | 1.2 |
| Usual care alone | 41 | 7.2 | 2.6 |
The treatment
Shockwave + usual care
Shockwave, twice a week for 3 weeks
- Sessions
- 6, two a week
- Pulses
- 4,000 per session · to the muscles beside the spine
- Strength
- 0.25mJ/mm² at 4–8 pulses a second, adjusted to comfort
- Numbing
- Not mentioned
- Device
- Dornier
- Everyone also got
- Antiviral, nerve-pain and anti-inflammatory medicines, plus posture and activity advice
Compared with: The same medicines and advice without shockwave
Settings are what each study used, not a prescription.
Who took part
82 adults aged 50–80 in hospital with shingles pain on the chest or lower back, all within a month of it starting; 41 also had shockwave.
Side effects
The paper did not report on side effects.
All the numbers and the full appraisal
Every reported result
The results, in numbers.
Adults 50–80 years with thoracic/lumbar segmental zoster pain lasting≤1 month, admitted May 2023–June 2024. MRI abnormalities were found in 74/82. Uncontrolled disease, anticoagulation, spinal infection/tumor, fracture and incomplete records were excluded.
Source reports this participant group.
Source reports this participant group.
Pain intensity3 reported outcomes
Pain intensity
NRS points
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| Usual care plus ESWT | 41 | 7.1 (SD 1) | 4.9 (SD 0.8) |
| Usual care | 41 | 7.2 (SD 1.1) | 5.3 (SD 1) |
Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.
ESWT plus usual care versus usual care
Source-reported between-group test
Reported group means; within-group change is not a between-group treatment effect.
Analysis details and source
Mean ± SD as printed. No effect or confidence interval reconstructed.
Pain intensity
NRS points
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| Usual care plus ESWT | 41 | 7.1 (SD 1) | 2.4 (SD 0.9) |
| Usual care | 41 | 7.2 (SD 1.1) | 3.3 (SD 1.1) |
Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.
ESWT plus usual care versus usual care
Source-reported between-group test
Reported group means; within-group change is not a between-group treatment effect.
Analysis details and source
Mean ± SD as printed. No effect or confidence interval reconstructed.
Pain intensity
NRS points
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| Usual care plus ESWT | 41 | 7.1 (SD 1) | 1.2 (SD 0.6) |
| Usual care | 41 | 7.2 (SD 1.1) | 2.6 (SD 1) |
Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.
ESWT plus usual care versus usual care
Source-reported between-group test
Reported group means; within-group change is not a between-group treatment effect.
Analysis details and source
Mean ± SD as printed. No effect or confidence interval reconstructed.
Sleep quality3 reported outcomes
Sleep quality
PSQI points
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| Usual care plus ESWT | 41 | 12.3 (SD 2.1) | 8.5 (SD 1.9) |
| Usual care | 41 | 12.6 (SD 2.4) | 9.6 (SD 2) |
Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.
ESWT plus usual care versus usual care
Source-reported between-group test
Reported group means; within-group change is not a between-group treatment effect.
Analysis details and source
Mean ± SD as printed. No effect or confidence interval reconstructed.
Sleep quality
PSQI points
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| Usual care plus ESWT | 41 | 12.3 (SD 2.1) | 5.2 (SD 1.6) |
| Usual care | 41 | 12.6 (SD 2.4) | 7.3 (SD 2.1) |
Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.
ESWT plus usual care versus usual care
Source-reported between-group test
Reported group means; within-group change is not a between-group treatment effect.
Analysis details and source
Mean ± SD as printed. No effect or confidence interval reconstructed.
Sleep quality
PSQI points
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| Usual care plus ESWT | 41 | 12.3 (SD 2.1) | 3.6 (SD 1.3) |
| Usual care | 41 | 12.6 (SD 2.4) | 6.1 (SD 2) |
Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.
ESWT plus usual care versus usual care
Source-reported between-group test
Reported group means; within-group change is not a between-group treatment effect.
Analysis details and source
Mean ± SD as printed. No effect or confidence interval reconstructed.
Spinal imaging score3 reported outcomes
Spinal imaging score
SMIS points
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| Usual care plus ESWT | 41 | 54.6 (SD 7.3) | 51 (SD 6.1) |
| Usual care | 41 | 53.9 (SD 6.8) | 52.2 (SD 6.5) |
Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.
ESWT plus usual care versus usual care
Source-reported between-group test
Reported group means; within-group change is not a between-group treatment effect.
Analysis details and source
Mean ± SD as printed. No effect or confidence interval reconstructed.
Spinal imaging score
SMIS points
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| Usual care plus ESWT | 41 | 54.6 (SD 7.3) | 45.8 (SD 5.4) |
| Usual care | 41 | 53.9 (SD 6.8) | 50.3 (SD 6.2) |
Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.
ESWT plus usual care versus usual care
Source-reported between-group test
Reported group means; within-group change is not a between-group treatment effect.
Analysis details and source
Mean ± SD as printed. No effect or confidence interval reconstructed.
Spinal imaging score
SMIS points
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| Usual care plus ESWT | 41 | 54.6 (SD 7.3) | 40.2 (SD 5) |
| Usual care | 41 | 53.9 (SD 6.8) | 47.1 (SD 5.9) |
Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.
ESWT plus usual care versus usual care
Source-reported between-group test
Reported group means; within-group change is not a between-group treatment effect.
Analysis details and source
Mean ± SD as printed. No effect or confidence interval reconstructed.
Postherpetic neuralgia1 reported outcome
Postherpetic neuralgia
people
Source-reported unadjusted counts; allocation was not random.
Analysis details and source
Descriptive source-reported counts; no effect estimate reconstructed.
NRS≤31 reported outcome
NRS≤3
people
Source-reported unadjusted counts; allocation was not random.
Analysis details and source
Descriptive source-reported counts; no effect estimate reconstructed.
PSQI≤51 reported outcome
PSQI≤5
people
Source-reported unadjusted counts; allocation was not random.
Analysis details and source
Descriptive source-reported counts; no effect estimate reconstructed.
SMIS improvement≥20%1 reported outcome
SMIS improvement≥20%
people
Source-reported unadjusted counts; allocation was not random.
Analysis details and source
Descriptive source-reported counts; no effect estimate reconstructed.
Early null comparisons1 reported outcome
Early null comparisons
Qualitative finding
At 3 months ESWT/control NRS 1.2±0.6/2.6±1.0, PSQI 3.6±1.3/6.1±2.0, SMIS 40.2±5.0/47.1±5.9; reported p<.001. PHN occurred in 2/41 versus 13/41. Week 1 NRS and SMIS comparisons were nonsignificant (p=.067/.327), despite later differences. These are unadjusted associations, not prevention proof.
Analysis details and source
Qualitative extraction preserves the source scope.
How treatment was delivered
Dornier electromagnetic shockwave device applied to the paraspinal muscles adjacent to the affected segments, 4,000 pulses/session, 0.25 mJ/mm², 4–8 Hz, pressure reported 1–5 MPa; twice weekly for 3 weeks, 6 sessions. Settings adjusted to tolerance/location.
Both groups received antivirals, neuropathic analgesics such as pregabalin/amitriptyline, NSAIDs, supportive care and individualized postural/activity advice. Actual medication doses and adherence were not controlled in the comparison.
The article reports no data on treatment adverse events or side effects. PHN is a disease outcome, not an ESWT safety event.
Selection/confounding acknowledged; three-month follow-up, small sample and no adjusted analysis. SMIS called validated but scoring items and reliability coefficients are not supplied. Several reported p values warrant checking against means/SD/n. Government/Hebei funding and no conflicts declared. A correction changes institutional affiliation from Technology to Engineering; ethics text still uses Technology.
Findings checked against the full source by a separate automated reviewer.
Limitations noted by the reviewers
- Selection/confounding acknowledged; three-month follow-up, small sample and no adjusted analysis. SMIS called validated but scoring items and reliability coefficients are not supplied. Several reported p values warrant checking against means/SD/n. Government/Hebei funding and no conflicts declared. A correction changes institutional affiliation from Technology to Engineering; ethics text still uses Technology.
Source-linked critical reading
nonrandom comparative
Technical source record
Complete local PDF text read, including all article body sections, tables, figure captions, discussion, disclosures and references. The article lists no supplementary material.
Patients who received extra shockwave sessions had better later scores, but treatment choice and other care may explain part of the difference. Reliable prevention of persistent zoster pain remains unproven.
Was adjunctive ESWT associated with better pain, sleep and imaging outcomes after acute zoster?
Single-centre retrospective comparison of 82 hospitalized patients,41 receiving usual care and 41 usual care plus ESWT. Treatment depended on physician judgment, patient preference and device availability; no randomization or confounder-adjusted effect was reported.
Adults 50–80 years with thoracic/lumbar segmental zoster pain lasting≤1 month, admitted May 2023–June 2024. MRI abnormalities were found in 74/82. Uncontrolled disease, anticoagulation, spinal infection/tumor, fracture and incomplete records were excluded.
Dornier electromagnetic shockwave device applied to the paraspinal muscles adjacent to the affected segments, 4,000 pulses/session, 0.25 mJ/mm², 4–8 Hz, pressure reported 1–5 MPa; twice weekly for 3 weeks, 6 sessions. Settings adjusted to tolerance/location.
Both groups received antivirals, neuropathic analgesics such as pregabalin/amitriptyline, NSAIDs, supportive care and individualized postural/activity advice. Actual medication doses and adherence were not controlled in the comparison.
NRS, PSQI and the 20-item 0–100 spinal imaging score SMIS were assessed at 48 hours after admission, one week, and one/three months after discharge. The one-week anchor is inconsistent: Methods says after treatment, Results after initiation, although the course lasts three weeks. PHN beyond 90 days from onset conflicts with the introduction’s rash-resolution reference.
At 3 months ESWT/control NRS 1.2±0.6/2.6±1.0, PSQI 3.6±1.3/6.1±2.0, SMIS 40.2±5.0/47.1±5.9; reported p<.001. PHN occurred in 2/41 versus 13/41. Week 1 NRS and SMIS comparisons were nonsignificant (p=.067/.327), despite later differences. These are unadjusted associations, not prevention proof.
The article reports no data on treatment adverse events or side effects. PHN is a disease outcome, not an ESWT safety event.
Selection/confounding acknowledged; three-month follow-up, small sample and no adjusted analysis. SMIS called validated but scoring items and reliability coefficients are not supplied. Several reported p values warrant checking against means/SD/n. Government/Hebei funding and no conflicts declared. A correction changes institutional affiliation from Technology to Engineering; ethics text still uses Technology.
Limited to early segmental zoster in selected inpatients. It cannot justify replacing antiviral/neuropathic care or treating imaging change as a demonstrated mechanism of neural recovery.
Prospective randomization, standardized medicines, transparent SMIS validation, prespecified PHN timing and 6–12 month follow-up would test the hypothesis.
Read the original article.
Extracorporeal shockwave therapy for zoster-associated pain: A retrospective analysis based on spinal musculoskeletal imbalance
Cheng F, Yu Y, Zhang J. · Medicine (Baltimore) · 2026
Open the publication record or available full-text files.
Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →